Homes
Public Notices
News
Local news
Editor’s Pick
Pittsburgh
Local Government
Roads, Travel and Traffic
20 Years of Gas Drilling
Regional
U.S. and World
Business
Sports
HS Sports
College Sports
Penguins
Pirates
Steelers
Athlete of the Week
Wild Things
Pony Baseball
Outdoors
Columns
Opinion
Columns
Editorials
Letters to the Editor
Op Eds
Living
Neighbors
School News
Entertainment
Home and Garden
Food
Police Beat
Obituaries
Classifieds
Legal Notices
Sponsored Content
e-Edition
close
Washington County
Greene County
Mon Valley
News
Local news
Police Beat
Pittsburgh
Local Government
Roads, Travel and Traffic
Helping The Helpers
20 Years of Gas Drilling
Regional
U.S. and World
Business News
Sports
High School Sports
College Sports
Penguins
Pirates
Steelers
Wild Things
Pro Sports
Outdoors
Sports Column
Obituaries
Opinion
Columns
Editorials
Letters to the Editor
Op-Ed
Living
Neighbors
Health and Wellness
Entertainment
Home and Garden
Classifieds
Contact Us
Advertise With Us
Customer Service
Contact Information
Submission Forms
Statement of Values
Misc
Special Sections
Events
Sponsored Content
Newsletter
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries
(CSE:
QNTM
)
22.50
+2.10 (+10.29%)
Streaming Delayed Price
Updated: 3:16 PM EDT, Oct 14, 2025
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about QNTM
< Previous
1
2
3
4
Next >
InvestorNewsBreaks – Quantum BioPharma Ltd. (NASDAQ: QNTM) (CSE: QNTM) Reports Positive Phase 1 Safety Results for Lucid-MS
August 05, 2025
Via
Investor Brand Network
Quantum Biopharma Announces Positive Results of the Clinical Study Report (CSR) for the Phase 1 Multiple Ascending Dose (MAD) Clinical Trial of Experimental Multiple Sclerosis Drug Lucid-21-302 (Lucid-MS)
August 05, 2025
From
Quantum BioPharma
Via
GlobeNewswire
InvestorNewsBreaks – Quantum BioPharma Ltd. (NASDAQ: QNTM) (CSE: QNTM) Opposes Motion to Dismiss in $700 Million Market Manipulation Lawsuit
August 04, 2025
Via
Investor Brand Network
Quantum BioPharma Files Reply and Provides Update on Court Case Seeking Damages Against CIBC, RBC and Others in Excess of $700,000,000 USD for Possible Stock Price Manipulation/Spoofing
August 04, 2025
From
Quantum BioPharma
Via
GlobeNewswire
InvestorNewsBreaks – Quantum BioPharma Ltd. (NASDAQ: QNTM) (CSE: QNTM) Portfolio Company Unbuzzd Wellness Launches $5 Million Regulation D Offering
July 31, 2025
Via
Investor Brand Network
Topics
Initial Public Offering
Quantum BioPharma Licensee Unbuzzd Wellness Inc. Commences Reg D Capital Raise Campaign to Fund Growth and Possible IPO
July 31, 2025
This Offering Will Not Dilute Quantum BioPharma Shareholders
From
Quantum BioPharma
Via
GlobeNewswire
Quantum BioPharma Makes Strategic Investment in GameStop Corp.
July 22, 2025
From
Quantum BioPharma
Via
GlobeNewswire
Quantum BioPharma Submits its Candidate Breakthrough Patented Drug for Multiple Sclerosis for Fast-Track Program in the United Kingdom
July 08, 2025
From
Quantum BioPharma
Via
GlobeNewswire
Quantum BioPharma Licensee Unbuzzd Wellness Inc. Launches $5 Million Reg D Capital Raise to Fund Growth and Path to Possible Initial Public Offering
June 26, 2025
Engages leading marketing firm MZ Digital and crowdfunding platform Dealmaker to successfully execute raise
From
Quantum BioPharma
Via
GlobeNewswire
Singular Research Reports on Quantum BioPharma Ltd.'s Strategic Advances and Pipeline Progress
June 18, 2025
Los Angeles, California--(Newsfile Corp. - June 18, 2025) - Singular Research, a leading provider of independent research on small-cap companies,...
Via
Newsfile
Topics
Initial Public Offering
Quantum BioPharma Announces First Person with Multiple Sclerosis (MS) Scanned in Joint Study with Massachusetts General Hospital
June 17, 2025
Joint Clinical Study with Massachusetts General Hospital Could Pave the Way for Testing Efficacy of Quantum’s Investigational MS drug, Lucid-21-302
From
Quantum BioPharma
Via
GlobeNewswire
Quantum BioPharma Announces Intention to Declare Special Dividend of Contingent Value Rights (CVRs) Linked to Future Litigation Settlement Proceeds
June 13, 2025
From
Quantum BioPharma
Via
GlobeNewswire
Quantum Biopharma Purchases More Bitcoin (BTC) Bringing the Total Investment in Digital Assets to USD $5,000,000
June 10, 2025
From
Quantum BioPharma
Via
GlobeNewswire
Quantum BioPharma Clarifies It Has Not Changed Its Name
June 03, 2025
From
Quantum BioPharma
Via
GlobeNewswire
InvestorNewsBreaks – Quantum BioPharma Ltd. (NASDAQ: QNTM) (CSE: QNTM) Finalizes $2.35 Million Settlement with Former CEO Raza Bokhari
May 30, 2025
Via
Investor Brand Network
Quantum BioPharma Receives $2.35 Million USD from a Mutually-Agreed Global Legal Settlement with Dr. Raza Bokhari
May 30, 2025
Dr. Raza Bokhari, Company’s Former CEO, Paid $2.35 Million USD in Non-Dilutive Cash to Cover Legal and Other Costs Determined in the Arbitral Award Over the Past 4 Years
From
Quantum BioPharma
Via
GlobeNewswire
Quantum Biopharma Licensee Celly Nutrition Retains Leading Audit Firm MNP LLP to Advance Capital Raise and Go-Public Readiness and Changes Name To Unbuzzd Wellness Inc.
May 29, 2025
From
Quantum BioPharma
Via
GlobeNewswire
Quantum BioPharma Receives Ethics Committee Approval for Phase 2 Clinical Trial of FSD202 for Nociplastic Pain in Patients with Idiopathic Mast Cell Activation Syndrome
May 28, 2025
From
Quantum BioPharma
Via
GlobeNewswire
Quantum BioPharma Partners with BitGo to Securely Store its Crypto Currency Assets
May 21, 2025
From
Quantum BioPharma
Via
GlobeNewswire
Quantum Biopharma Announces Signing of an Agreement with a Global Pharmaceutical Contract Research Organization to Prepare an IND (Investigational New Drug) Application Package for Lucid-21-302 (Lucid-MS), A First-In-Class Treatment for Multiple Sclerosis
May 20, 2025
From
Quantum BioPharma
Via
GlobeNewswire
Quantum Biopharma Purchases an Additional USD $1 Million of Bitcoin and Other Cryptocurrencies to Hold BTC Treasury and To Generate Staking Revenue. Bringing the Total Investment in Digital Assets to USD $4,500,000
May 19, 2025
From
Quantum BioPharma
Via
GlobeNewswire
Quantum BioPharma to Attend Sidoti Micro-Cap Investor Conference and the AGP Virtual Healthcare Conference
May 16, 2025
From
Quantum BioPharma
Via
GlobeNewswire
Quantum BioPharma Announces Completion of Dosing in 90-Day Repeated Dose Oral Toxicity and Toxicokinetic Studies for Lucid-MS for Multiple Sclerosis
May 12, 2025
From
Quantum BioPharma
Via
GlobeNewswire
Quantum Biopharma Files Amended Complaint Against CIBC World Markets, RBC Dominion Securities and Others, Seeking Damages in Excess of $700,000,000 USD, for Possible Stock Price Manipulation/Spoofing
May 05, 2025
From
Quantum BioPharma
Via
GlobeNewswire
Quantum BioPharma to Host Business Update Conference Call on Tuesday, May 6, 2025 at 4:30 p.m. Eastern Time
April 24, 2025
From
Quantum BioPharma
Via
GlobeNewswire
Quantum Biopharma Announces Advocate Against Naked Short Selling and Stock Manipulation, Kevin Malone Appointed as Board Advisor
April 22, 2025
From
Quantum BioPharma
Via
GlobeNewswire
BioMedNewsBreaks — Quantum BioPharma Ltd. (NASDAQ: QNTM) (CSE: QNTM) Issues Corporate Update
April 21, 2025
Via
Investor Brand Network
Quantum Biopharma Wins Reconsideration Motion by Dr. Raza Bokhari at the Court of Appeal for Ontario
April 14, 2025
Awards in favour of Quantum BioPharma Totalling $180,000 upheld and is now due
From
Quantum BioPharma
Via
GlobeNewswire
Quantum BioPharma Licensee Celly Nutrition Announces Landmark Partnership with the Asian American Trade Associations Council (AATAC) to Expand Retail Availability of its Alcohol Detox Beverage unbuzzd™
April 10, 2025
From
Quantum BioPharma
Via
GlobeNewswire
Quantum BioPharma Licensee Celly Nutrition Launches unbuzzd in Puerto Rico
April 03, 2025
From
Quantum BioPharma
Via
GlobeNewswire
< Previous
1
2
3
4
Next >
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms Of Service
.
Starting at $3.75
/
week.
Subscribe Today